Indolent Lymphoma
From the Journals
CAR-T outcomes similar among diverse cancer patients
Black, Hispanic, White, and Asian cancer patients showed comparable responses to CAR-T therapy, a study indicates.
Latest News
EU approves new blood and lung cancer drugs
At its April meeting, the European Medicine Agency OKed two new drugs for some lymphoma and lung cancer patients.
News
FDA investigates possible increased risk of death with lymphoma drug
Clinical trial findings of “possible increased risk of death” associated with the drug umbralisib for CLL prompted the FDA to announce...
From the Journals
Severe COVID two times higher for cancer patients
Conference Coverage
Combo provides ‘broad benefit’ across NHL subtypes
Adding copanlisib to rituximab improved progression-free survival, but overall survival data are not mature.
From the Journals
Don’t delay: Cancer patients need both doses of COVID vaccine
For patients with cancer, immune response to the first dose of the Pfizer COVID-19 vaccine is reduced, and there is a need for a booster dose at...
Conference Coverage
Survey quantifies COVID-19’s impact on oncology
Oncologists detail how COVID-19 has impacted care, caregivers, continuing medical education, and clinical trials.
From the Journals
Hepatitis screening now for all patients with cancer on therapy
All patients with cancer who are candidates for systemic therapy should be screened for hepatitis B, says the American Society of Clinical...
Latest News
Follicular lymphoma treatment can benefit patients 80 years and older
FL-directed therapy was associated with an overall survival benefit, which persisted.
Conference Coverage
Survival data reported from largest CAR T trial in B-cell lymphoma
ORLANDO – Progression-free survival results were best among complete responders and patients with primary mediastinal large B-cell lymphoma or...
Conference Coverage
5F9 plus rituximab take a bite out of drug-resistant NHL
AMSTERDAM – The combination thwarts a mechanism that non-Hodgkin lymphomas use to evade immune surveillance.